08 January 2025
ImmuPharma PLC
("ImmuPharma" or the "Company")
IMMUPHARMA at JP MORGAN CONFERENCE and BIOTECH SHOWCASE
11-16 JAN 2025, SAN FRANCISCO
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CEO of the R&D subsidiary ImmuPharma Biotech will be attending both the JP Morgan Conference and the Biotech Showcase from 11-16 January 2025, in San Francisco.
The JP Morgan conference and Biotech Showcase are annual premier partnering events, designed to provide biotechnology companies with the opportunity to present to and connect with global Biopharma companies and investors.
The advances made by ImmuPharma with the P140 program, particularly in the latter part of 2024, have led to significant interest from leading Biopharmaceutical companies and we are progressing discussions as we move to establish global licensing agreements.
There have been eleven $1bn+ licensing deals for immunology assets across the BioPharma industry from 2023 to late September 2024. The current trend suggests that Immunology and Autoimmune drug assets are becoming very highly sought by the leading BioPharma companies.
Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma said: "Attending and taking meetings at both the JP Morgan conference and the Biotech Showcase offers the opportunity to continue discussions across our whole unique portfolio and specifically with global BioPharma companies that have an interest in autoimmune diseases demonstrated within our P140 technology platform. Our focus remains on track to establish global partnering opportunities across all of our programs."
Ends
| For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140,is a first-in class "immune tolerance restorer" for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases that share the same mechanism of action.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
